EUVIMEDEUVIMED entdecken
Crossref

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Julian M Yabut, Daniel J Drucker iD

Endocrine Reviews · 12.01.2023 · 44 (1) · 14-32

DOI: 10.1210/endrev/bnac018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 30.07.2022. Verfasst von Julian M Yabut und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 185-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: CIHR, Sinai Health-Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the treatment of type 2 diabetes (T2D) and obesity. GLP-1RA exhibit a favorable safety profile and reduce the incidence of major adverse cardiovascular events in people with T2D. Considerable preclinical data, supported by the results of clinical trials, link therapy with GLP-RA to reduction of hepatic inflammation, steatosis, and fibrosis. Mechanistically, the actions of GLP-1 on the liver are primarily indirect, as hepatocytes, Kupffer cells, and stellate cells do not express the canonical GLP-1R. GLP-1RA reduce appetite and body weight, decrease postprandial lipoprotein secretion, and attenuate systemic and tissue inflammation, actions that may contribute to attenuation of metabolic-associated fatty liver disease (MAFLD). Here we discuss evolving concepts of GLP-1 action that improve liver health and highlight evidence that links sustained GLP-1R activation in distinct cell types to control of hepatic glucose and lipid metabolism, and reduction of experimental and clinical nonalcoholic steatohepatitis (NASH). The therapeutic potential of GLP-1RA alone, or in combination with peptide agonists, or new small molecule therapeutics is discussed in the context of potential efficacy and safety. Ongoing trials in people with obesity will further clarify the safety of GLP-1RA, and pivotal studies underway in people with NASH will define whether GLP-1–based medicines represent effective and safe therapies for people with MAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2HumansGlucagon-Like Peptide 1ObesityInflammationHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

cardiovascular diseasediabetesglucagon-like-peptide-1liver diseasenon-alcoholic steatosisobesity

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Daniel J Drucker

Förderung

  • CIHR
  • Sinai Health-Novo Nordisk Foundation

Zitieren

APA

Yabut, J. M., & Drucker, D. J. (2023). Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews, 44(1), 14-32. https://doi.org/10.1210/endrev/bnac018

Vancouver

Yabut JM, Drucker DJ. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews. 2023;44(1):14-32. doi:10.1210/endrev/bnac018

BibTeX
@article{Yabut2023,
  author = {Yabut, Julian M and Drucker, Daniel J},
  title = {Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease},
  journal = {Endocrine Reviews},
  year = {2023},
  volume = {44},
  number = {1},
  pages = {14--32},
  doi = {10.1210/endrev/bnac018}
}
Kostenlos starten →